Medtronic has secured FDA clearance for its new InPen insulin delivery system application, paving the way for the launch of its smart multiple daily injection (MDI) system. This system integrates with the recently FDA-cleared, next-generation Simplera continuous glucose monitor (CGM).
The InPen system stands out as the first on the market to recommend corrections for missed or inaccurate insulin doses. It aims to provide real-time, personalized insights for individuals on MDI therapy, addressing the challenges they face in daily insulin dosing decisions. Medtronic emphasizes that this smart MDI system is designed to reduce the guesswork involved in diabetes management, meeting a critical unmet need for MDI users.
